Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/23549134 below:

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Comparative Study

Affiliations

• ¹ Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721-0202, USA.

• PMID: 23549134
• DOI: 10.1161/STROKEAHA.111.000402

Item in Clipboard

Comparative Study

Amanda R Harrington et al. Stroke. 2013 Jun.

• ¹ Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721-0202, USA.

• PMID: 23549134
• DOI: 10.1161/STROKEAHA.111.000402

Item in Clipboard

Background and purpose: To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin.

Methods: A Markov decision-analysis model was constructed using data from clinical trials to evaluate lifetime costs and quality-adjusted life-years of novel oral anticoagulants compared with warfarin. The modeled population was a hypothetical cohort of 70-year-old patients with nonvalvular atrial fibrillation, increased risk for stroke (CHADS2 ≥ 1), renal creatinine clearance ≥ 50 mL/min, and no previous contraindications to anticoagulation. The willingness-to-pay threshold was $50 000/quality-adjusted life-years gained.

Results: In the base case, warfarin had the lowest cost of $77 813 (SD, $2223), followed by rivaroxaban 20 mg ($78 738 ± $1852), dabigatran 150 mg ($82 719 ± $1959), and apixaban 5 mg ($85 326 ± $1512). Apixaban 5 mg had the highest quality-adjusted life-years estimate at 8.47 (SD, 0.06), followed by dabigatran 150 mg (8.41 ± 0.07), rivaroxaban 20 mg (8.26 ± 0.06), and warfarin (7.97 ± 0.04). In a Monte Carlo probabilistic sensitivity analysis, apixaban 5 mg, dabigatran 150 mg, rivaroxaban 20 mg, and warfarin were cost-effective in 45.1%, 40%, 14.9%, 0% of the simulations, respectively.

Conclusions: In patients with nonvalvular atrial fibrillation and an increased risk of stroke prophylaxis, apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg were all cost-effective alternatives to warfarin. The cost-effectiveness of novel oral anticoagulantss was dependent on therapy pricing in the United States and neurological events associated with rivaroxaban 20 mg.

Keywords: Markov model; anticoagulation; atrial fibrillation; cost-effectiveness; intracranial hemorrhage; stroke.

PubMed Disclaimer

• Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.

  Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA. Coyle D, et al. Value Health. 2013 Jun;16(4):498-506. doi: 10.1016/j.jval.2013.01.009. Epub 2013 Apr 23. Value Health. 2013. PMID: 23796283

• Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.

  Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, Choudhry NK. Canestaro WJ, et al. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):724-31. doi: 10.1161/CIRCOUTCOMES.113.000661. Epub 2013 Nov 12. Circ Cardiovasc Qual Outcomes. 2013. PMID: 24221832

• US cost-effectiveness analysis of apixaban compared with warfarin, dabigatran and rivaroxaban for nonvalvular atrial fibrillation, focusing on equal value of life years and health years in total.

  Atreja N, Johannesen K, Subash R, Bektur C, Hagan M, Hines DM, Dunnett I, Stawowczyk E. Atreja N, et al. J Comp Eff Res. 2025 Jan;14(1):e240163. doi: 10.57264/cer-2024-0163. Epub 2024 Nov 28. J Comp Eff Res. 2025. PMID: 39606884 Free PMC article.

• Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.

  Kansal AR, Zheng Y, Pokora T, Sorensen SV. Kansal AR, et al. Best Pract Res Clin Haematol. 2013 Jun;26(2):225-37. doi: 10.1016/j.beha.2013.07.012. Epub 2013 Aug 1. Best Pract Res Clin Haematol. 2013. PMID: 23953910 Review.

• Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.

  Harris K, Mant J. Harris K, et al. Int J Clin Pract. 2013 Jul;67(7):647-55. doi: 10.1111/ijcp.12177. Epub 2013 Apr 28. Int J Clin Pract. 2013. PMID: 23621153 Free PMC article. Review.

• Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.

  Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Lip GY. Dorian P, et al. Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006. Epub 2014 Feb 9. Eur Heart J. 2014. PMID: 24513791 Free PMC article.

• Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.

  Krejczy M, Harenberg J, Marx S, Obermann K, Frölich L, Wehling M. Krejczy M, et al. J Thromb Thrombolysis. 2014 May;37(4):507-23. doi: 10.1007/s11239-013-0989-6. J Thromb Thrombolysis. 2014. PMID: 24221805

• Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting.

  Wu Y, Zhang C, Gu ZC. Wu Y, et al. Front Cardiovasc Med. 2021 Jun 29;8:675200. doi: 10.3389/fcvm.2021.675200. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34268343 Free PMC article.

• Apixaban and oral implications.

  Lopez-Galindo M, Bagán JV. Lopez-Galindo M, et al. J Clin Exp Dent. 2015 Oct 1;7(4):e528-34. doi: 10.4317/jced.52470. eCollection 2015 Oct. J Clin Exp Dent. 2015. PMID: 26535102 Free PMC article. Review.

• Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis.

  Noviyani R, Youngkong S, Nathisuwan S, Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, McKay G, Sritara P, Attia J, Thakkinstian A. Noviyani R, et al. BMJ Evid Based Med. 2022 Aug;27(4):215-223. doi: 10.1136/bmjebm-2020-111634. Epub 2021 Oct 11. BMJ Evid Based Med. 2022. PMID: 34635480 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3